-
Oxygen is
essential to life.We seek to help people maintain health,
enhance their skin's appearance and improve quality of life through clinical and topical oxygen delivery via our proprietary Oxycyte® perfluorocarbon-based emulsions, gels and lotions.
-
Oxygen Biotherapeutics is the tissue oxygenation company.
Oxygen is essential to life. When that supply is shut off the results can range from minor to devastating.
-
Our goal is to help the human body maintain a sufficient supply of oxygen.
The mission of Oxygen Biotherapeutics is to research, develop and market oxygen related topical and intravenous products based on our perfluorocarbon technology.
Our Mission
The mission of Oxygen Biotherapeutics is to research, develop and market oxygen related topical and intravenous products based on our perfluorocarbon technology.
Clinical Trials
Currently, we have one product candidate, Oxycyte PFC emulsion, in Phase IIb clinical trials in Switzerland and Israel for use in treating traumatic brain injury (TBI).
Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte®
Company on Track to Resume Phase IIb Traumatic Brain Injury Trial Later This Year
MORRISVILLE, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company ("the Company") focused on developing perfluorocarbon-based intravenous and topical drug candidates, today announced it has achieved the critical milestone of securing an exclusive supply of cGMP-compliant Oxycyte®, the Company's proprietary perfluorocarbon based emulsion, that will take the Company through the current Phase II clinical trial for traumatic brain injury (TBI) and well into Phase III trials. more..
About Oxygen Biotherapeutics
Oxygen Biotherapeutics is the tissue oxygenation company
Oxygen is essential to life. When that supply is shut off the results can range from minor to devastating. At Oxygen Biotherapeutics, our goal is to help the human body maintain a sufficient oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is suddenly interrupted or diminished.
Currently, we are developing medical and cosmetic products designed to deliver oxygen to specific tissues in the body that are deprived of oxygen. Our most advanced product, Oxycyte PFC, is in Phase IIb clinical trials in Switzerland and Israel for the traumatic brain injury. Oxycyte PFC is an intravenously delivered perfluorocarbon-based drug that we believe has therapeutic benefits for acute ischemic conditions. The first cohort of the Phase IIb trail is complete and efforts are being made to resume the trials later this fiscal year with planned expansions in other countries. more..